Cadonilimab, a novel bispecific antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), has shown enhanced antitumor activity with a manageable safety profile in NSCLC cases in early-phase clinical trials (6). Here, PDCD1 is linked to non-small cell lung carcinoma.